Literature DB >> 23334396

Adiponectin promotes functional recovery after podocyte ablation.

Joseph M Rutkowski1, Zhao V Wang, Ae Seo Deok Park, Jianning Zhang, Dihua Zhang, Ming Chang Hu, Orson W Moe, Katalin Susztak, Philipp E Scherer.   

Abstract

Low levels of the adipocyte-secreted protein adiponectin correlate with albuminuria in both mice and humans, but whether adiponectin has a causative role in modulating renal disease is unknown. Here, we first generated a mouse model that allows induction of caspase-8-mediated apoptosis specifically in podocytes upon injection of a construct-specific agent. These POD-ATTAC mice exhibited significant kidney damage, mimicking aspects of human renal disease, such as foot process effacement, mesangial expansion, and glomerulosclerosis. After the initial induction, both podocytes and filtration function recovered. Next, we crossed POD-ATTAC mice with mice lacking or overexpressing adiponectin. POD-ATTAC mice lacking adiponectin developed irreversible albuminuria and renal failure; conversely, POD-ATTAC mice overexpressing adiponectin recovered more rapidly and exhibited less interstitial fibrosis. In conclusion, these results suggest that adiponectin is a renoprotective protein after podocyte injury. Furthermore, the POD-ATTAC mouse provides a platform for further studies, allowing precise timing of podocyte injury and regeneration.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23334396      PMCID: PMC3559480          DOI: 10.1681/ASN.2012040414

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  56 in total

1.  Fat apoptosis through targeted activation of caspase 8: a new mouse model of inducible and reversible lipoatrophy.

Authors:  Utpal B Pajvani; Maria E Trujillo; Terry P Combs; Puneeth Iyengar; Linda Jelicks; Kevin A Roth; Richard N Kitsis; Philipp E Scherer
Journal:  Nat Med       Date:  2005-06-19       Impact factor: 53.440

2.  Two gene fragments that direct podocyte-specific expression in transgenic mice.

Authors:  Marcus J Moeller; Silja K Sanden; Abdulsalam Soofi; Roger C Wiggins; Lawrence B Holzman
Journal:  J Am Soc Nephrol       Date:  2002-06       Impact factor: 10.121

Review 3.  Adipose tissue, inflammation, and cardiovascular disease.

Authors:  Anders H Berg; Philipp E Scherer
Journal:  Circ Res       Date:  2005-05-13       Impact factor: 17.367

4.  Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity.

Authors:  Kazuyuki Hida; Jun Wada; Jun Eguchi; Hong Zhang; Masako Baba; Aya Seida; Izumi Hashimoto; Tatsuo Okada; Akihiro Yasuhara; Atsuko Nakatsuka; Kenichi Shikata; Shinji Hourai; Junichiro Futami; Eijiro Watanabe; Yasushi Matsuki; Ryuji Hiramatsu; Shigeru Akagi; Hirofumi Makino; Yashpal S Kanwar
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-19       Impact factor: 11.205

5.  Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene.

Authors:  Bryan L Wharram; Meera Goyal; Jocelyn E Wiggins; Silja K Sanden; Sabiha Hussain; Wanda E Filipiak; Thomas L Saunders; Robert C Dysko; Kenji Kohno; Lawrence B Holzman; Roger C Wiggins
Journal:  J Am Soc Nephrol       Date:  2005-08-17       Impact factor: 10.121

6.  Genetic engineering of glomerular sclerosis in the mouse via control of onset and severity of podocyte-specific injury.

Authors:  Taiji Matsusaka; Jing Xin; Suguri Niwa; Kazuto Kobayashi; Akira Akatsuka; Hiroomi Hashizume; Qing-Cheng Wang; Ira Pastan; Agnes B Fogo; Iekuni Ichikawa
Journal:  J Am Soc Nephrol       Date:  2005-03-09       Impact factor: 10.121

7.  Effects of body-weight loss and captopril treatment on proteinuria associated with obesity.

Authors:  M Praga; E Hernández; A Andrés; M León; L M Ruilope; J L Rodicio
Journal:  Nephron       Date:  1995       Impact factor: 2.847

8.  A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity.

Authors:  Terry P Combs; Utpal B Pajvani; Anders H Berg; Ying Lin; Linda A Jelicks; Mathieu Laplante; Andrea R Nawrocki; Michael W Rajala; Albert F Parlow; Laurelle Cheeseboro; Yang-Yang Ding; Robert G Russell; Dirk Lindemann; Adam Hartley; Glynn R C Baker; Silvana Obici; Yves Deshaies; Marian Ludgate; Luciano Rossetti; Philipp E Scherer
Journal:  Endocrinology       Date:  2003-10-23       Impact factor: 4.736

9.  Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity.

Authors:  Utpal B Pajvani; Meredith Hawkins; Terry P Combs; Michael W Rajala; Tom Doebber; Joel P Berger; John A Wagner; Margaret Wu; Annemie Knopps; Anny H Xiang; Kristina M Utzschneider; Steven E Kahn; Jerrold M Olefsky; Thomas A Buchanan; Philipp E Scherer
Journal:  J Biol Chem       Date:  2003-12-29       Impact factor: 5.157

10.  Implication of CD38 gene in podocyte epithelial-to-mesenchymal transition and glomerular sclerosis.

Authors:  Krishna M Boini; Min Xia; Jing Xiong; Caixia Li; Lori P Payne; Pin-Lan Li
Journal:  J Cell Mol Med       Date:  2012-08       Impact factor: 5.310

View more
  68 in total

1.  Inhibition of Epidermal Growth Factor Receptor Activation Is Associated With Improved Diabetic Nephropathy and Insulin Resistance in Type 2 Diabetes.

Authors:  Zhilian Li; Yan Li; Jessica M Overstreet; Sungjin Chung; Aolei Niu; Xiaofeng Fan; Suwan Wang; Yinqiu Wang; Ming-Zhi Zhang; Raymond C Harris
Journal:  Diabetes       Date:  2018-06-29       Impact factor: 9.461

2.  The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia.

Authors:  Mary E Haas; Amy E Levenson; Xiaowei Sun; Wan-Hui Liao; Joseph M Rutkowski; Sarah D de Ferranti; Valerie A Schumacher; Philipp E Scherer; David J Salant; Sudha B Biddinger
Journal:  Circulation       Date:  2016-07-05       Impact factor: 29.690

3.  Effects of erythropoietin receptor activity on angiogenesis, tubular injury, and fibrosis in acute kidney injury: a "U-shaped" relationship.

Authors:  Mingjun Shi; Brianna Flores; Peng Li; Nancy Gillings; Kathryn L McMillan; Jianfeng Ye; Lily Jun-Shen Huang; Sachdev S Sidhu; Yong-Ping Zhong; Maria T Grompe; Philip R Streeter; Orson W Moe; Ming Chang Hu
Journal:  Am J Physiol Renal Physiol       Date:  2017-11-29

Review 4.  Obesity and renovascular disease.

Authors:  Xin Zhang; Lilach O Lerman
Journal:  Am J Physiol Renal Physiol       Date:  2015-06-03

Review 5.  The many secret lives of adipocytes: implications for diabetes.

Authors:  Philipp E Scherer
Journal:  Diabetologia       Date:  2018-11-21       Impact factor: 10.122

Review 6.  Impact of bariatric surgery on cardiovascular and renal complications of diabetes: a focus on clinical outcomes and putative mechanisms.

Authors:  William P Martin; Neil G Docherty; Carel W Le Roux
Journal:  Expert Rev Endocrinol Metab       Date:  2018-09-19

7.  Renal Function in Type 2 Diabetes Following Gastric Bypass.

Authors:  Adrian T Billeter; Stefan Kopf; Martin Zeier; Katharina Scheurlen; Lars Fischer; Thilo M Schulte; Hannes G Kenngott; Barbara Israel; Philipp Knefeli; Markus W Büchler; Peter P Nawroth; Beat P Müller-Stich
Journal:  Dtsch Arztebl Int       Date:  2016-12-09       Impact factor: 5.594

Review 8.  Adiponectin as a tissue regenerating hormone: more than a metabolic function.

Authors:  Tania Fiaschi; Francesca Magherini; Tania Gamberi; Pietro Amedeo Modesti; Alessandra Modesti
Journal:  Cell Mol Life Sci       Date:  2013-12-10       Impact factor: 9.261

Review 9.  Adiponectin, driver or passenger on the road to insulin sensitivity?

Authors:  Risheng Ye; Philipp E Scherer
Journal:  Mol Metab       Date:  2013-04-19       Impact factor: 7.422

10.  Inhibition of pannexin-1 channel activity by adiponectin in podocytes: Role of acid ceramidase activation.

Authors:  Guangbi Li; Qinghua Zhang; Jinni Hong; Joseph K Ritter; Pin-Lan Li
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2018-08-01       Impact factor: 4.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.